Asparlas
Payments companies reported to CMS as associated with Asparlas. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Asparlas, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Asparlas
These are the largest totals companies reported as associated with Asparlas. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Guillermo Deangulo | Miami, FL | Pediatric Hematology-Oncology | $49,948.01 |
| Natalie Bezler | Hartford, CT | Pediatric Hematology-Oncology | $25,275.71 |
| Mitchell Cairo | Hawthorne, NY | Pediatric Hematology-Oncology | $18,381.94 |
| Rebecca Johnson | Tacoma, WA | Pediatric Hematology-Oncology | $15,956.86 |
| Samuel Pabon Rivera | San Antonio, TX | Pediatric Hematology-Oncology | $8,869.22 |
| Aaron Logan | San Francisco, CA | Hematology & Oncology | $7,590.00 |
| Victor Wong | San Diego, CA | Pediatric Hematology-Oncology | $5,477.80 |
| Lewis Silverman | New York, NY | Pediatric Hematology-Oncology | $4,937.90 |
| Samuel Klempner | Los Angeles, CA | Hematology & Oncology | $3,740.00 |
| James Harding | New York, NY | Hematology & Oncology | $3,740.00 |
Prescribed Asparlas?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.